ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Huntsman Cancer Institute Joins NCCN: Howard cancer Center To Honor Mandela

November 7, 1997

ASCO Draft Recommendations Define Meaningful Trial Outcomes

April 26, 2013

Cancer Panel To Form Committee On Breast Cancer

October 11, 1991

In Brief: Arkansas, Iowa Appoint Center Directors; Broder Moves To Gene Sequencing Venture

August 14, 1998

December Business & Regulatory Report included in this issue.

December 12, 2003

Rimer, Boxer Reappointed to NCAB; 4 Others Named

June 28, 1996